Purpose: Contrast-enhanced ultrasound plays an expanding role in oncology, but its applicability to molecular imaging is hindered by a lack of nanoscale contrast agents that can reach targets outside the vasculature. Gas vesicles (GVs)-a unique class of gas-filled protein nanostructures-have recently been introduced as a promising new class of ultrasound contrast agents that can potentially access the extravascular space and be modified for molecular targeting. The purpose of the present study is to determine the quantitative biodistribution of GVs, which is critical for their development as imaging agents. Procedures: We use a novel bioorthogonal radiolabeling strategy to prepare technetium-99m-radiolabeled ([ 99m Tc])GVs in high radiochemical purity. We use single photon emission computed tomography (SPECT) and tissue counting to quantitatively assess GV biodistribution in mice.
Introduction
Contrast-enhanced ultrasound (CEUS), with lipid-or protein-stabilized gas microbubbles, plays an important role in patient care and is evolving as a fundamental screening tool in cardiology, oncology and gynecology [1] . CEUS is used in a variety of clinical applications such as detecting and characterizing focal liver lesions [2] , evaluating cerebral circulation for stroke [3] 
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Considerable efforts have been directed toward the development of targeted microbubbles to allow visualization of specific biomarkers of disease using CEUS (i.e., molecular imaging). Unfortunately, after two decades of investigation, there is only one example of molecular ultrasound imaging in the clinic, i.e., targeted ultrasound imaging of kinase insert domain receptor in prostate [10, 11] , ovarian, and breast cancer patients [12] . The limited number of agents undergoing advanced testing is due to both regulatory issues and limitations of existing microbubbles, which are restricted to the vascular space due to their large size and limited in vivo stability (seconds to minutes). Furthermore, other candidates including solid [13] , liquid [14] , hollow, or phase-change contrast agents have been investigated and demonstrate weak echogenicity [15, 16] and poor stability and require cumbersome synthesis. As a result and to maximize the utility of targeted molecular ultrasound imaging, there is a need to discover and fully characterize novel nanosized ultrasound imaging agents with strong echogenicity, longer in vivo stability, and modifiable surface to allow the agents to bind to a wider array of disease biomarkers.
A promising ultrasound contrast model based on naturally occurring nanostructures, called gas vesicles (GVs), has been reported [17] . The biological function of the GVs is to provide buoyancy to a wide range of aqueous haloarchaea and cyanobacteria. GVs have been studied for over 100 years [18] , resulting in considerable knowledge of their biochemical and genetic structure [19] . GVs are gas-filled, protein-shelled nanostructures with typical widths of 45-250 nm and lengths of 100-600 nm that exclude water and are permeable to gas [20] . Because of these properties, Shapiro et al. recently explored the potential of GVs for contrast enhanced ultrasound imaging [17] . They showed that GVs exhibit non-linear ultrasonic properties, which could be due to buckling [21] , substantially improve contrast in ultrasound images and have no adverse side effects in mice. Due to their small volume, they have the potential to access extravascular targets via the enhanced and permeable retention effect [22] , a feature that can be further enhanced through the ability to genetically engineer their protein shell [23] . While the in vitro and in vivo US properties of GVs have been characterized, it is crucial to understand their pharmacokinetic properties and excretion route as the basis from which to create targeted constructs and fully exploit their potential as molecular ultrasound contrast agents. Here, we report a mild and convenient methodology to functionalize and radiolabel GVs and the first quantitative spatio-temporal distribution study of radiolabeled GVs in mice using single photon emission computed tomography (SPECT) and quantitative tissue counting.
Material and Methods

Gas Vesicle Preparation
GV culturing, isolation and purification were carried out as previously described [17, 24] . In brief, Halobacteria sp. NCR-1 (Carolina Biological Supply, Burlington, NC) were cultured in high salt Carolina media, at 42°C, in an incubation shaker at 100 revolution per minutes (rpm) (Ecotron, Infors AG, Switzerland). GVs were then isolated using TMC lysis buffer and purified through multiple rounds (5 to 6) of centrifugation at 300 rcf with the centrifuge maintained at 4°C.
Radiolabeling of GVs with Technetium-99m
The technetium-99m-labeled tetrazine ([ 99m Tc]Tz), compound 3 (Fig. 1a) , was prepared following literature methods in good radiochemical yield and high purity (Suppl. Fig. S1a , b, in electronic supplementary material (ESM)) [25, 26] . Trans-cyclooctene (TCO)-conjugated GVs (TCO-GVs) were prepared by adding (E)-cyclooct-4-enyl-2,5-dioxopyrrolidin-1-yl carbonate (TCO-NHS) (855.1 μg, 3.2 μmol; Click Chemistry Tools, 1016-100) in dimethyl sulfoxide (DMSO, 197.3 μl) to a solution of GVs (OD 500 nm = 55.2, 1.8 ml) in PBS at pH 8. The solution was left to mix on a shaker for 2.5 h and the desired TCO-GVs purified by dialysis using 6-8 kD dialysis membrane submerged in PBS overnight (Spectra/ Por 1 Dialysis Membrane, Spectrum Labs, USA). The TCO-GVs were then concentrated using centrifugal flotation at 300 rcf for 15 min (Fig. 1b) . Compound 3 (29 MBq, 100 μl) was then added to a solution of TCOGVs (OD 500 nm = 50, 400 μl) at room temperature and left shaking for 30 min. Tc-99m-labeled GVs ([ 99m Tc]GVs) were then washed with PBS and purified from any residual 3 using a single round of centrifugal flotation (Fig. 1c) . To assess the purity, a sample of the mixture was taken before and after purification, sonicated and injected into a HiTrap size-exclusion cartridge attached to a high-performance liquid chromatography (HPLC) fitted with a gamma detector. The column was eluted with 100 mM ammonium bicarbonate in water at 1 ml/min flow rate (isocratic elution 0-8 min 100 %).
Stability Study in Plasma
To determine the stability of [
99m Tc]GVs in plasma, samples were prepared following the procedures described above. To assess the purity, a sample of the mixture was taken and spotted on an iTLC-SG glass microfiber chromatography paper (Agilent Technologies, SGI0001) plate and run with a mobile phase of 75 % methanol, 25 % water, and visualized on a Bioscan AR-2000 Imaging Scanner. The purified [
99m Tc]GVs (3.4 MBq, 100 μl) was then added to mouse plasma (900 μl) and incubated on a shaker for 120 min at 37°C. Samples were taken at 2, 5, 10, 20, 60, and 120 min and analyzed for purity by RadioTLC (Suppl. Fig. S2, ESM) . At 60 and 120 min, 450 μl samples were taken, and the GV layer was separated from the plasma by centrifugal flotation (400 rcf, 10 min). The activity in the plasma and GV layers was measured using a dose calibrator. 
Biodistribution Studies
All experimental procedures were approved by the Animal Care Committees at Sunnybrook Research Institute and McMaster University.
Quantitative Tissue Counting
Studies were performed on healthy female, 5-6-week-old CD1 mice (Charles River Laboratory, Kingston, NY). Mice were injected intravenously (i.v.) with 0. 99m Tc]GVs studies were performed at 5, 20, 60, and 120 min post-injection (n = 3 per time point). Blood, adipose, bone, brain, gall bladder, heart, kidneys, large intestine and cecum (with contents), liver, lungs, lymph nodes (axillary and brachial), pancreas, skeletal muscle, small intestine (with contents), spleen, stomach (with contents), thyroid/trachea, and bladder with urine and tail were collected, weighed, and counted in an automated gamma counter (PerkinElmer Wallac Wizard 1470 gamma counter, PerkinElmer, Waltham, USA). Decay correction was used to normalize organ activity measurements to time of dose preparation for data calculations with respect to the injected dose (reported as % injected dose (ID) per gram and % ID per organ).
SPECT/CT Imaging
Studies were performed following i.v. injection of intact or collapsed [
99m Tc]GVs at a constant flow rate of 500 μl/min (New Era Pump Systems, NE-1000, NY,USA) via the tail vein of healthy CD1 or SHO mice (Charles River Laboratory, 4-6 weeks of age, n = 6). Mice were anesthetized with isoflurane (2-2.5 % maintenance, Univentor 410, Univentor Ltd., Malta) and prepared for the GV injection. Collapsed GVs were obtained by reaching the collapse pressure inside a syringe (by capping the nozzle and pushing the piston). Once collapsed, GVs lose their ultrasonic contrast properties and cannot be investigated with ultrasound. Following catheterization, mice were placed in prone position on the mouse bed, which maintained its body temperature at 37°C. The amount of activity injected ranged from 2.2 to 20.5 MBq. The volume injected ranged from 80 to 330 μl, and the concentration ranged from 18 to 33 OD 500 nm . SPECT imaging was performed during and immediately after GV injection.
Fast dynamic whole body scans were performed on a SPECT imaging system (VECTor+, MILabs, Utrecht, The Netherlands) using a high-energy collimator (HE-UHR-RM, MILabs) with 156 clustered multi-pinholes collimator of 1.8 mm. An image was acquired prior to [
99m Tc]GVs injection. Following activity measurement in the syringe with a dose calibrator (Capintec Inc., NJ, USA), subsequent images were then collected by running the same acquisition with a scan time ranging from 33 to 84 s and for up to 120 min during and after injection of [ 99m Tc]GVs. For calibration of SPECT images, a 1-ml syringe filled with a solution of known activity of [
99m Tc]GVs in PBS (measured by the dose calibrator for each experiment) was scanned using the same collimator after the animal experiment. To obtain anatomical details, anesthetized mice were then scanned using an in vivo X-ray microtomography system (SkyScan 1176, Bruker Corp., Kontich, Belgium) at 35 μm pixel resolution and 360°scanning with a rotation step of 1.4°per image, 66 ms exposition time, 1 mm aluminum filter, 65 kV, and 385 μA.
SPECT/CT Data Processing and Statistical Analysis
All SPECT images were reconstructed using the pixel-based maximum likelihood expectation maximization (POSEM, VECTor+ software, MILabs, The Netherlands) algorithm using 16 subsets, 15 iterations, and a small voxel size of 0.512 mm 3 [27, 28] . During reconstruction, correction for scattering is performed using a triple-energy window method [29] , i.e., Tc-99m energy window with the photopeak window centered at the peak of the data set (142 keV), with a width set to 20 %, together with the left and right background windows centered at 125 and 159 keV, with a width set to 4.5 and 3.6 %, respectively. After reconstruction, the images were corrected for decay using the half-life of Tc-99m (6.02 h), attenuation correction was applied, and quantified SPECT images were obtained by using a calibration factor [30, 31] . Images were then processed using a semi-automatic segmentation based on the local mean analysis and 3D rendering tools in PMOD (PMOD Technologies LLC, v3.7, Zurich, Switzerland). Briefly, the segmentation method first separates the mouse body from the background noise using a histogram based algorithm. Secondly, the local mean time activity curve (TAC) and background noise are computed in the vicinities of selected points within mouse organs. Finally, the image is segmented into regions, which are merged according to their TACs in a hierarchical manner [32] . The resulting segmentation was checked slice by slice for imperfections, and any corrections including erosion, dilation, and/or deletion of voxels were made using PMOD morphological operations. TACs were generated according to individual segmented organs and are reported by averaging together data acquired within a time period of 10 min to yield the mean and associated standard error of the mean.
CT images were reconstructed using an implementation of the Feldkamp cone-beam algorithm and beam hardening, and ring artifacts were corrected in Nrecon (Bruker Corp.) [33] . The registration of CT and SPECT images and the movies were generated using PMOD Fusion tools (PMOD Technologies LLC).
Statistical analyses were performed using NCSS 11 (NCSS, LLC. Kaysville, UT, USA). All data are expressed as mean ± SEM where n is the number of observations in the dynamic in vivo SPECT biodistribution study. The reported standardized uptake values (%ID/cm 3 ) for each tissue were analyzed over the time period studied using two-sample test followed by a Mann-Whitney U test and a KolmogorovSmirnov test. An alpha error level of 5 % was used for the tests.
Fluorescence Imaging from Histology
GVs were labeled with a fluorophore (Alexa-488, Sigma, USA) using standard amino-N-hydroxysuccinimide crosslinking [23] . Two healthy mice were injected i.v. either with Alexa-488 tagged GVs or native GVs (control) (OD 500 nm = 20, 130 μl) and euthanized 20 min following injection. The liver and spleen were collected, embedded in optimal cutting temperature compound, and snap frozen in nitrogen, then stored in a − 80°C freezer. Subsequently, the liver and spleen tissues were sectioned (4-5 μm, Cryostat, LEICA CM 3050 S, USA). Slides were then observed using an Olympus microscope (Olympus VS120 Virtual Slide Microscope, VS120-L100-W, ON, Canada) with identical acquisition parameters. Images were stored in the proprietary format and, later, visualized on a personal computer using OlyVIA (OLYMPUS OlyVIA 2.9). For each liver and spleen, up to three sections were observed.
Results
Radiolabeling
Most Tc-99m-labeling procedures require the use of reducing agents or harsh conditions [26, 34] ; consequently, an indirect approach to radiolabel GVs was developed. The approach took advantage of the highly efficient and rapid bioorthogonal reaction between trans-cyclooctene and tetrazine [35] . First, excess of (E)-cyclooct-4-enyl-2,5-dioxopyrrolidin-1-yl carbonate (TCO-NHS) was added to GVs to react with the amine groups present on the GV shell. Any residual TCO-NHS was removed by dialysis and TCOGVs solution concentrated by centrifugal flotation. This was then followed by the addition of a novel [
99m Tc]Tz which was recently reported [25] Fig. S1a, ESM) . Following purification, the gamma trace only exhibited one peak representing [ 99m Tc]GVs. The desired product was isolated in 59 % radiochemical yield with 9 99 % radiochemical purity (Suppl. Fig. S1b, ESM) .
The stability study revealed that, after incubation of the [ (Table S1 , ESM). In addition, 31 % of GVs after 60 min are still intact, while the rest had either collapsed or had non-specific binding to plasma components (Table S2 , ESM). The activity seen in the plasma layer is likely collapsed GVs rather than [ 99m Tc]Tz based on the radioTLC data (Suppl. Fig. S2, ESM) . This is consistent with the covalent nature of the bond between the components which is known to be stable in vivo.
Biodistribution: Ex Vivo Tissue Counting and SPECT
The distribution of [ Tc]GV injection, more than 5 % ID/g uptake in the gall bladder, liver, lungs, spleen, and bladder/urine while all other mouse organs or fluids typically exhibited less than 2 % ID/g uptake (Fig. 2a) . A small amount of [ 99m Tc]GVs was detected in the blood 5 min following injection which eventually decreased to 0.5 % ID/ g after 2 h. Uptake at sites that showed early and high localization remained high throughout the duration of the study. The biodistribution of [ 99m Tc]Tz alone also showed high gall bladder and small intestine concentrations, but there was significantly less activity in the liver, spleen, and lungs (particularly at later time points). It also showed faster blood clearance compared to [ 99m Tc]GVs (Fig. 2b) . In Fig. 3 , the 3D maximum intensity projections (MIP) of the in vivo dynamic SPECT data showed the spatial extent and signal intensity variations in the volume occupied by [ 99m Tc]GVs in mouse organs at time points corresponding to those of the tissue counting studies. There was no large spatial variation in signal intensities observed 2 h following [ 99m Tc]GVs injection; therefore, the spatial uptake of [ 99m Tc]GVs in a given organ was relatively uniform. Overall, 3D MIP findings correlated with the ex vivo tissue counting biodistribution findings.
Likewise, ex vivo tissue counting and in vivo SPECT quantitative biodistributions were also in good overall agreement at the studied time points (Fig. 4) , notably the reticuloendothelial system (RES) uptake (lungs, liver, spleen), the increase localization over time in the duodenum/small intestine, and the relatively short lived presence of GVs in the blood.
In Fig. 5a , 3D segmentation rendering of the mouse organs allowed the calculation of the volume occupied by [ (Table S3 , ESM). The volumes of these organs derived from the segmentation are similar to these found in healthy mice in the literature, e.g., the liver and the gall bladder volumes [36, 37] . The in vivo dynamic uptake of [ 99m Tc]GVs in segmented organs is reported in Fig. 5b . The overall uptake of native versus collapsed [ (Fig. 5b) . In contrast, [ 99m Tc]GVs had a slow uptake in the duodenum for the first 20 min, but the uptake increased over time (Fig. 5b) . [ 99m Tc]GV uptake, reported as an average between 10 and 120 min in % ID/cm 3 ± SD, was consistently observed in the liver (30 ± 2), spleen (4 ± 1), lungs (11 ± 1), gall bladder (76 ± 24), as well as in the duodenum and small intestine (21 ± 7), and bladder (8 ± 4) (video S1a and b, ESM). The averaged uptake rate constant of the gall bladder was 2-, 4-, and 9-fold faster than the uptake rate constants of the liver, the lungs, and the spleen, respectively (Table S4, ESM) .
Fluorescence Imaging
To confirm and better understand the spatial distribution of GVs at the microscopic level in liver and spleen tissues, fluorescence imaging on histology was performed. GVs were successfully tagged with Alexa-488 fluorophore (Alexa488-GVs) and were allowed to circulate long enough to distribute in all mouse organs including in the small intestines. Native GVs did not exhibit any fluorescent signals in the liver or in spleen tissues. In contrast, there was a marked and consistent fluorescent signal from Alexa488-GVs in the liver and spleen tissues (Fig. 6) .
Discussion
This study is the first to report the radiolabeling and biodistribution of GVs using both ex vivo tissue counting and SPECT imaging in mice. The labeling was performed using bioorthogonal chemistry between TCO-functionalized GVs and a Tc-99m-labeled tetrazine. The indirect approach avoided degradation of the GVs and non-specific labeling that could occur when using conditions typically employed during direct technetium labeling procedures. With this method, [ 99m Tc]GVs were produced in a good radiochemical yield and high purity where the radiolabel-GV conjugate demonstrated high stability in plasma.
Twenty minutes following administration, the biodistribution and imaging studies of the labeled GVs in organs revealed that the reticuloendothelial system (RES) absorbed 84 % of native and collapsed [ 99m Tc]GVs with the biliary system and small intestine assimilating the majority of the remaining material (13 %). Almost no [ 99m Tc]GVs remained in the blood 2 min after their injection, and they were more rapidly taken up by the gall bladder than the liver. Fluorescence imaging of the liver and spleen tissues further confirmed these findings.
RES Uptake
The uptake of radiolabeled GVs in non-target tissues is not surprisingly due to resident mature macrophages located close to the vessel walls [38] , removing [ 99m Tc]GVs from blood circulation rapidly. Furthermore, uptake and retention in the liver, spleen, and lungs is likely from Kupffer, red pulp macrophages, and reticular cells, respectively, present in these tissues. Given the nanometer size, lemon shape, negatively charged surface (− 49 mV) of the Halobacterium salinarum GVs, and their low dispersibility/ hydrophobicity [20] , their rapid uptake by the RES was similar to other types of nanoparticles [39, 40] . Indeed, intact and degraded [ 99m Tc]GV accumulation and saturation in the liver are likely due to their size since the liver sieve, i.e., the existence of vascular fenestrations measuring 50-100 nm along the liver margin [41] , would potentially facilitate non-specific uptake of individual radiolabeled GVs and degraded products. Likewise, [ 99m Tc]GVs and degraded products were hardly taken up by the kidneys since only smaller-sized nanoparticles with diameters below 5 nm are filtered by the renal system when delivered intravenously [42] . Furthermore, the lemon shape and ability to change shape of the [ 99m Tc]GVs, during gas exchange, could also be factors playing a role in biodistribution and, especially, in their spatial distribution in a given organ since Black et al. showed that differences in shape of radiolabeled gold nanoparticles clearly influenced their uptake and spatial distribution not only in tumors but also in the liver [43] .
Gall Bladder and Intestine Uptake
Interestingly, uptake within the biliary system and intestines accounted for 13 % of [ 99m Tc]GVs 20 min following administration. Of these organs, uptake in the gall bladder and duodenum was seen immediately, with an increase in uptake in these organs up to 20 min post injection. Thereafter, uptake was observed in the rest of the small intestine. Since no [ 99m Tc]GVs were observed in the stomach, these results suggest that radiolabeled GVs were captured by the hepatocytes in the liver, then secreted through the hepatic ducts and stored into the gall bladder. Assuming the When the bile is secreted, further degraded radiolabeled GVs were likely subsequently released from the gall bladder to the duodenum through the common bile duct that joins the common hepatic duct and connects to the duodenum. Hence, the distribution in the gall bladder and small intestine is therefore likely explained by the size of individual radiolabeled GVs and/or cluster of radiolabeled GVs and of the presence of fragmented [ 99m Tc]GVs that are all compounds too large to be cleared by the kidneys [42] .
GVs as Potential Ultrasound Contrast Agent
The biodistribution studies showed a relatively short-lived presence of GVs in the blood. This limits the utility of native GVs for tumor imaging as GVs will likely not circulate long enough to extravasate into target tissues. Ongoing research efforts are focused on investigating the impact of shell alterations of native GVs on their biodistribution as well as the effect of pegylation of native and modified GVs on their pharmacokinetic properties. In addition, a better understanding of the integrity and degradation of radiolabeled GVs, in particular those with surface modifications to prolong circulation, will also need to be further investigated.
Notably, no acute toxicity or adverse effects in mice were observed in our study where up to five times higher concentrations were used than in previous studies [17] . However, more extensive toxicity studies on the optimal construct once developed will be needed prior to translation.
Conclusion
A convenient method for radiolabeling GVs with Tc-99m along with the first quantitative biodistribution study of [ 99m Tc]GVs was reported. Results in healthy mice showed, not unexpectedly, a rapid uptake of radiolabeled GVs by the RES, providing a baseline for enhancing the in vivo properties of this novel class of ultrasound contrast agents. The reported labeling strategy conveniently offers the means to assess the impact of ongoing efforts associated with adding different pharmacokinetic modifiers and targeting molecules. 
